Non Small Cell Lung Cancer (NSCLC)

Stage I-III, Resectable

Standard Risk

Scheduled for Resection

Completely Resected

ALK Mutation

LUN0115
Adjuvant
Durvalumab for Early Stage NSCLC Patients with ctDNA Minimal Residual Disease
PI: Neal Stanford

ECOGE4512
Phase III
Crizotinib vs Observation in NSCLC w/ Anaplastic Lymphoma Kinase (ALK) Fusion Protein Tumors
PI: Wakelee ECOG-ACRIN

LUN0101
Phase III
Chemotherapy
+ Pembrolizumab in Neoadjuvant/Adjuvant Tx Resectable Stage IIB / IIA NSCLC
PI: Wakelee Sponsor: Merck Sharp & Dohme Corp.